Sutro Biopharma, Inc. (STRO) financial statements (2021 and earlier)

Company profile

Business Address 310 UTAH AVE., SUITE 150
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments368281250115118125153
Cash and cash equivalents20664654451219
Short-term investments16221718572113113134
Receivables67597107
Other undisclosed current assets4433312
Total current assets:378292258127129136162
Noncurrent Assets
Property, plant and equipment131211101099
Long-term investments and receivables  614162515
Long-term investments  614162515
Restricted cash and investments1100000
Other noncurrent assets2223322
Total noncurrent assets:16151926283627
TOTAL ASSETS:394307278154156172189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1411991298
Accounts payable6556655
Accrued liabilities9653654
Deferred revenue151624231920 
Debt    166
Contract with customer, liability21
Other liabilities1330111
Total current liabilities:30303532333636
Noncurrent Liabilities
Long-term debt and lease obligation25242424967
Long-term debt, excluding current maturities25242424967
Liabilities, other than long-term debt891116172026
Deferred revenue6811151620 
Contract with customer, liability26
Deferred rent credit1000000
Other liabilities0000000
Total noncurrent liabilities:32333540262633
Total liabilities:62637172596269
Stockholders' equity
Stockholders' equity attributable to parent3322442078298110120
Common stock0000000
Additional paid in capital560412392297293291287
Accumulated other comprehensive income0000000
Accumulated deficit(228)(168)(185)(215)(196)(181)(168)
Total stockholders' equity:3322442078298110120
TOTAL LIABILITIES AND EQUITY:394307278154156172189

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenue from related parties   3665
Gross profit:81897111211
Operating expenses(33)(28)(26)(26)(26)(25)(24)
Operating loss:(25)(11)(16)(19)(15)(13)(14)
Nonoperating income
(Investment Income, Nonoperating)
0001111
Interest and debt expense(1)(1)(1)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(25)(11)(17)(19)(14)(12)(13)
Other undisclosed loss from continuing operations(0)      
Loss before gain (loss) on sale of properties:(25)(11)(17)(19)(14)(12)(13)
Other undisclosed net loss(34)  (1)(1)  
Net loss:(60)(11)(17)(20)(15)(12)(13)
Other undisclosed net income (loss) attributable to parent 2847  (1)(1)
Net income (loss) available to common stockholders, diluted:(60)1730(20)(15)(13)(14)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(60)(11)(17)(20)(15)(12)(13)
Comprehensive loss:(60)(11)(17)(20)(15)(12)(13)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)2847(0)(0)(1)(1)
Comprehensive income (loss), net of tax, attributable to parent:(60)1730(20)(15)(13)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: